Ionis Pharmaceuticals Q4 Adjusted EPS $0.12 May Not Be Comparable To $(0.83) Estimate, Sales $325.00M Not Be Comparable To $174.76M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ionis Pharmaceuticals reported a Q4 adjusted EPS of $0.12, which may not be directly comparable to the estimated $(0.83). Additionally, their sales reached $325.00M, also not directly comparable to the estimated $174.76M.
February 21, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ionis Pharmaceuticals reported a significantly higher Q4 adjusted EPS of $0.12 compared to the estimated $(0.83) and sales of $325.00M, surpassing the $174.76M estimate.
The substantial outperformance in both EPS and sales compared to estimates suggests a strong financial performance for the quarter, which is likely to positively influence investor sentiment and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100